Elsevier

Current Opinion in Immunology

Volume 41, August 2016, Pages 39-46
Current Opinion in Immunology

New concepts in HIV-1 vaccine development

https://doi.org/10.1016/j.coi.2016.05.011Get rights and content
Under a Creative Commons license
open access

Highlights

  • Immune correlates of protection are guiding HIV-1 vaccine development.

  • RV144 follow-on trials aim to generate antibody responses to the V1V2 region of Env.

  • Immunogens are being tested to generate polyfunctional Env antibody responses.

  • Passive transfer of broadly neutralizing antibodies is being tested in clinical trials.

  • Replicating viral vectors may establish a pool of effector memory T-cells.

With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine efficacy trials in humans, complemented by active and passive immunization studies in non-human primates, have identified several key vaccine-induced immunological responses that may correlate with protection against HIV-1 infection. Potential correlates of protection in these studies include V2-specific, polyfunctional, and broadly neutralizing antibody responses, as well as effector memory T cell responses. Here we review how these correlates of protection are guiding current approaches to HIV-1 vaccine development. These approaches include improvements on the ALVAC-HIV/AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in Thailand, adenovirus serotype 26 vectors with gp140 boosting, intravenous infusions of bNAbs, and replicating viral vectors.

Cited by (0)